导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.81% | 3316/4773 |
| 近一周 | -1.66% | 629/5462 |
| 近一月 | 0.47% | 582/5421 |
| 近一季 | -0.22% | 781/5209 |
| 近半年 | -9.59% | 3519/4920 |
| 近一年 | -2.90% | 3032/4366 |
| 近两年 | 26.80% | 2419/2954 |
| 近三年 | 18.64% | 1524/2253 |
| 成立以来 | 116.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.20% 2185/4961 |
-10.55% 4123/5312 |
- - |
- - |
| 2025 | 7.55% 2921/4813 |
-4.70% 3214/3635 |
2.53% 1506/4076 |
7.37% 3454/4524 |
2.50% 930/4813 |
| 2024 | 25.73% 245/3463 |
9.17% 141/2808 |
2.61% 333/3014 |
11.60% 2495/3129 |
0.57% 1195/3463 |
| 2023 | -1.00% 487/2656 |
6.53% 676/2280 |
-1.00% 434/2385 |
0.80% 339/2515 |
-6.87% 1952/2655 |
| 2022 | -9.39% 173/2207 |
-5.32% 186/1919 |
1.80% 1419/2016 |
-9.41% 277/2113 |
3.77% 647/2208 |
| 2021 | 10.79% 418/1822 |
1.94% 237/1255 |
-0.03% 1121/1330 |
7.64% 175/1466 |
0.99% 1026/1822 |
| 2020 | 16.55% 775/1250 |
-9.58% 692/1028 |
2.61% 965/1067 |
16.17% 164/1164 |
8.14% 686/1184 |
| 2019 | 21.34% 651/1092 |
19.15% 630/754 |
-3.14% 377/804 |
-1.36% 649/850 |
6.59% 584/918 |
| 2018 | -21.50% 215/834 |
- - |
- - |
- - |
-9.64% 154/691 |
| 2017 | 15.84% 243/714 |
- - |
- - |
- - |
- - |
| 2016 | -0.57% 109/605 |
- - |
- - |
- - |
- - |
| 2015 | 3.21% 235/575 |
- - |
- - |
- - |
- - |
| 2014 | 63.14% 27/237 |
- - |
- - |
- - |
- - |
| 2013 | -9.29% 144/186 |
- - |
- - |
- - |
- - |
| 2012 | 4.60% 83/140 |
- - |
- - |
- - |
- - |
| 2011 | -23.66% 63/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 南方小康ETF联接A VS. 长安沪深300非周期A(740101) |